WallStreetZenWallStreetZen

NASDAQ: TRDA
Entrada Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their TRDA stock forecasts and price targets.

Forecast return on equity

Is TRDA forecast to generate an efficient return?

Company
N/A
Industry
339.39%
Market
216.29%

Forecast return on assets

Is TRDA forecast to generate an efficient return on assets?

Company
N/A
Industry
119.5%

TRDA earnings per share forecast

What is TRDA's earnings per share in the next 2 years based on estimates from 8 analysts?

Avg 1 year Forecast
-$4.28
Avg 2 year Forecast
-$4.40

TRDA revenue forecast

What is TRDA's revenue in the next 3 years based on estimates from 8 analysts?

Avg 1 year Forecast
$38.5M-37.45%
Avg 2 year Forecast
$56.6M-8.06%
Avg 3 year Forecast
$0.0-100%
TRDA's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

TRDA revenue growth forecast

How is TRDA forecast to perform vs Biotechnology companies and vs the US market?

Company
-28.9%
Industry
117.67%
Market
22.81%
TRDA's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
TRDA's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

TRDA vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
TRDA$10.82N/AN/A
DMAC$7.90$18.50+134.18%Strong Buy
BNTC$12.41$27.67+122.94%Buy
ALLO$1.80$6.50+261.11%Strong Buy
FBRX$32.04$67.00+109.11%Strong Buy
View Top Biotech Stocks

Entrada Therapeutics Stock Forecast FAQ

What is TRDA's earnings growth forecast for 2026-2027?

(NASDAQ: TRDA) Entrada Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 69.99%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 39.92%.

Entrada Therapeutics's earnings in 2026 is -$103,455,000.On average, 8 Wall Street analysts forecast TRDA's earnings for 2026 to be -$163,536,272, with the lowest TRDA earnings forecast at -$184,652,397, and the highest TRDA earnings forecast at -$121,594,487.

In 2027, TRDA is forecast to generate -$168,118,758 in earnings, with the lowest earnings forecast at -$189,896,076 and the highest earnings forecast at -$128,015,318.

If you're new to stock investing, here's how to buy Entrada Therapeutics stock.

What is TRDA's revenue growth forecast for 2026-2028?

(NASDAQ: TRDA) Entrada Therapeutics's forecast annual revenue growth rate of -28.9% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 117.67%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 22.81%.

Entrada Therapeutics's revenue in 2026 is $61,520,000.On average, 8 Wall Street analysts forecast TRDA's revenue for 2026 to be $1,470,714,267, with the lowest TRDA revenue forecast at $561,822,710, and the highest TRDA revenue forecast at $2,407,811,616. On average, 6 Wall Street analysts forecast TRDA's revenue for 2027 to be $2,161,641,543, with the lowest TRDA revenue forecast at $970,080,547, and the highest TRDA revenue forecast at $3,411,066,456.

In 2028, TRDA is forecast to generate $0 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $0.

What is TRDA's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: TRDA) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 119.5%.

What is TRDA's Earnings Per Share (EPS) forecast for 2026-2027?

(NASDAQ: TRDA) Entrada Therapeutics's current Earnings Per Share (EPS) is -$2.55. On average, analysts forecast that TRDA's EPS will be -$4.28 for 2026, with the lowest EPS forecast at -$4.83, and the highest EPS forecast at -$3.18. In 2027, TRDA's EPS is forecast to hit -$4.40 (min: -$4.97, max: -$3.35).

What is TRDA's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: TRDA) forecast ROE is N/A, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.